Adrenocortical Carcinoma Pipeline Therapeutics Gets a Boost With 20+ Active Pharma Players
Discover the latest drugs and treatment options in the Adrenocortical Carcinoma Pipeline. Dive into DelveInsight's comprehensive report today! @ Adrenocortical Carcinoma Pipeline Outlook
Key Takeaways from the Adrenocortical Carcinoma Pipeline Report
In May 2025, Corcept Therapeutics conducted a study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may benefit from continuing treatment.
DelveInsight's Adrenocortical Carcinoma Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Adrenocortical Carcinoma treatment.
The leading Adrenocortical Carcinoma Companies such as Corcept Therapeutics, Bristol-Myers Squibb, Enterome, Exelixis/Ipsen, Genentech and others.
Promising Adrenocortical Carcinoma Pipeline Therapies such as Pembrolizumab, Sunitinib, OSI-906, Iressa (ZD1839), Osilodrostat, TKM-080301, Axitinib, Dostarlimab, Chemotherapy, Ipilimumab, Nivolumab and others.
Stay ahead with the most recent pipeline outlook for Adrenocortical Carcinoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Adrenocortical Carcinoma Treatment Drugs
Adrenocortical Carcinoma Emerging Drugs Profile
Relacorilant: Corcept Therapeutics
Relacorilant is a non-steroidal, selective modulator of the glucocorticoid receptor, the receptor for cortisol which is activated when cortisol levels are high. Relacorilant does not bind to the body's other hormone receptors. Corcept is studying relacorilant as a potential treatment for a variety of serious disorders, including Cushing's syndrome and advanced adrenal, ovarian and pancreatic cancer.
Ipilimumab: Bristol-Myers Squibb
Yervoy is a recombinant, human monoclonal antibody that binds to the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4). CTLA-4 is a negative regulator of T-cell activity. Yervoy binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, CD80/CD86. Blockade of CTLA-4 has been shown to augment T-cell activation and proliferation, including the activation and proliferation of tumor infiltrating T-effector cells. Inhibition of CTLA-4 signaling can also reduce T-regulatory cell function, which may contribute to a general increase in T-cell responsiveness, including the anti-tumor immune response. The drug is in phase 2 of clinical trials for the treatment of adrenocortical carcinoma.
The Adrenocortical Carcinoma Pipeline Report Provides Insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Adrenocortical Carcinoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Adrenocortical Carcinoma Treatment.
Adrenocortical Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Adrenocortical Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Adrenocortical Carcinoma market
Explore groundbreaking therapies and clinical trials in the Adrenocortical Carcinoma Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New Adrenocortical Carcinoma Drugs
Adrenocortical Carcinoma Companies
Corcept Therapeutics, Bristol-Myers Squibb, Enterome, Exelixis/Ipsen, Genentech and others.
Adrenocortical Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
Adrenocortical Carcinoma Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Unveil the future of Adrenocortical Carcinoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Adrenocortical Carcinoma Market Drivers and Barriers
Scope of the Adrenocortical Carcinoma Market Report
Coverage- Global
Adrenocortical Carcinoma Companies- Corcept Therapeutics, Bristol-Myers Squibb, Enterome, Exelixis/Ipsen, Genentech and others.
Adrenocortical Carcinoma Pipeline Therapies such as Pembrolizumab, Sunitinib, OSI-906, Iressa (ZD1839), Osilodrostat, TKM-080301, Axitinib, Dostarlimab, Chemotherapy, Ipilimumab, Nivolumab and others.
Adrenocortical Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Adrenocortical Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Adrenocortical Carcinoma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Adrenocortical Carcinoma Companies, Key Products and Unmet Needs
Table of Contents
Introduction
Executive Summary
Adrenocortical Carcinoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Adrenocortical Carcinoma– DelveInsight's Analytical Perspective
Mid Stage Products (Phase II)
Ipilimumab: Bristol-Myers Squibb
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Relacorilant: Corcept Therapeutics
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Adrenocortical Carcinoma Key Companies
Adrenocortical Carcinoma Key Products
Adrenocortical Carcinoma- Unmet Needs
Adrenocortical Carcinoma- Market Drivers and Barriers
Adrenocortical Carcinoma- Future Perspectives and Conclusion
Adrenocortical Carcinoma Analyst Views
Adrenocortical Carcinoma Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
18 minutes ago
- CTV News
You can slow cognitive decline as you age, large study finds. Here's how
At 62, Phyllis Jones felt trapped in darkness. She was traumatized by her mother's recent death, ongoing pandemic stress and an increasingly toxic work environment. A sudden panic attack led to a medical leave. Her depression worsened until the day her 33-year-old son sadly told her, 'Mom, I didn't think I would have to be your caregiver at this stage in your life.' 'For me, that was the wake-up call,' Jones, now 66, told CNN. 'That's when I found the POINTER study and my life changed. What I accomplished during the study was phenomenal — I'm a new person.' The Protect Brain Health Through Lifestyle Intervention to Reduce Risk, or U.S. POINTER study, is the largest randomized clinical trial in the United States designed to examine whether lifestyle interventions can protect cognitive function in older adults. 'These are cognitively healthy people between the ages of 60 and 79 who, to be in the study, had to be completely sedentary and at risk for dementia due to health issues such as prediabetes and borderline high blood pressure,' said principal investigator Laura Baker, a professor of gerontology, geriatrics and internal medicine at Wake Forest University School of Medicine in Winston-Salem, North Carolina. Approximately one-half of the 2,111 study participants attended 38 structured team meetings over two years in local neighborhoods near Chicago, Houston, Winston-Salem, Sacramento, California, and Providence, Rhode Island. During each session, a trained facilitator provided guidance on how to exercise and eat for the brain, and explained the importance of socialization, the use of brain-training games, and the basics of brain health. The team leader also held the group accountable for logging blood pressure and other vitals. Physical and cognitive exams by a physician occurred every six months. At six team meetings, the other half of the study's participants learned about brain health and were encouraged to select lifestyle changes that best suited their schedules. This group was self-guided, with no goal-directed coaching. These participants also received physical and cognitive exams every six months. The two-year results of the US$50 million study, funded by the Alzheimer's Association, were simultaneously presented Monday at the 2025 Alzheimer's Association International Conference in Toronto and published in the journal JAMA. 'We found people in the structured program appeared to delay normal cognitive aging by one to nearly two years over and above the self-guided group — people who did not receive the same degree of support,' Baker said. 'However, the self-guided group improved their cognitive scores over time as well.' Exercise, diet and socializing are key Exercise was the first challenge. Like the other groups across the country, Jones and her Aurora, Illinois, team received YMCA memberships and lessons on how to use the gym equipment. Jones was told to use aerobic exercise to raise her heart rate for 30 minutes a day while adding strength training and stretching several times a week. At first, it wasn't easy. The study participants wore fitness trackers that monitored their activity, Jones said. 'After that first 10 minutes, I was sweating and exhausted,' she said. 'But we went slow, adding 10 minutes at a time, and we kept each other honest. Now I just love to work out.' Four weeks later, teams were given a new challenge — beginning the Mediterranean-DASH Intervention for Neurodegenerative Delay, or MIND diet. The diet combines the best of the Mediterranean diet with the salt restrictions of the DASH diet, which stands for Dietary Approaches to Stop Hypertension. 'They gave us a refrigerator chart with foods to limit and foods to enjoy,' Jones said. 'We had to eat berries and vegetables most days, including green leafy veggies, which was a separate item. We had to have 2 tablespoons of extra-virgin olive oil once every day.' Foods to limit included fried food, processed meat, dairy, cheese and butter. Restrictions were also in place for sugary sweets. 'But we could have dessert four times a week,' Jones added. 'That's awesome because you're not completely depriving yourself.' Another pillar of the program was requiring study participants to familiarize themselves with their vital signs, Wake Forest's Baker said. 'If at any point we asked them, 'What's your average blood pressure?' they should be able to tell us,' she said. 'We encouraged people to monitor their blood sugar as well.' Later came brain training, via memberships to a popular, Web-based cognitive training app. While some scientists say the benefits of such online brain programs have yet to be proven, Jones said she enjoyed the mental stimulation. Becoming better at socializing was another key part of the program. The researchers tasked teams with assignments, such as speaking to strangers or going out with friends. 'I found my best friend, Patty Kelly, on my team,' Jones said. 'At 81, she's older than me, but we do all sorts of things together — in fact, she's coming with me to Toronto when I speak at the Alzheimer's conference. 'Isolation is horrible for your brain,' she added. 'But once you get to a point where you are moving and eating healthy, your energy level changes, and I think you automatically become more social.' As the study progressed, the researchers reduced check-ins to twice a month, then once a month, Baker said. 'We were trying to get people to say, 'I am now a healthy person,' because if you believe that, you start making decisions which agree with the new perception of yourself,' she said. 'So in the beginning, we were holding their hands, but by the end, they were flying on their own,' Baker added. 'And that was the whole idea — get them to fly on their own.' 'Brain health is a long game' Because researchers tracked each team closely, the study has a wealth of data that has yet to be mined. 'On any given day, I could go into our web-based data system and see how much exercise someone's doing, whether they've logged into brain training that day, what's their latest MIND diet score, and whether they'd attended the last team meeting,' Baker said. 'We also have sleep data, blood biomarkers, brain scans and other variables, which will provide more clarity on which parts of the intervention were most successful.' Digging deeper into the data is important, Baker says, because the study has limitations, such as the potential for a well-known phenomenon called the practice effect. 'Even though we use different stimuli within tests, the act of taking a test over and over makes you more familiar with the situation — you know where the clinic is, where to park, you're more comfortable with your examiner,' she said. 'You're not really smarter, you're just more relaxed and comfortable, so therefore you do better on the test,' Baker said. 'So while we're thrilled both groups in US POINTER appear to have improved their global cognition (thinking, learning and problem-solving), we have to be cautious in our interpretations.' It's important to note the POINTER study was not designed to provide the more immersive lifestyle interventions needed for people with early stages of Alzheimer's, said Dr. Dean Ornish, a professor of medicine at the University of California, San Francisco. Ornish published a June 2024 clinical trial that found a strict vegan diet, daily exercise, structured stress reduction and frequent socialization could often stop the decline or even improve cognition in those already experiencing from early-stage Alzheimer's disease, not just for those at risk for it. 'The US POINTER randomized clinical trial is a landmark study showing that moderate lifestyle changes in diet, exercise, socialization and more can improve cognition in those at risk for dementia,' said Ornish, creator of the Ornish diet and lifestyle medicine program and coauthor of 'Undo It!: How Simple Lifestyle Changes Can Reverse Most Chronic Diseases.' 'It complements our randomized clinical trial findings which found that more intensive multiple lifestyle changes often improve cognition in those already diagnosed with early-stage Alzheimer's disease,' Ornish said. 'But the US POINTER study showed that more moderate lifestyle changes may be sufficient to help prevent it.' In reality, two years isn't sufficient to track brain changes over time, said study coauthor Maria Carillo, chief science officer of the Alzheimer's Association. 'We really want to make recommendations that are evidence based,' Carillo told CNN. 'That's why we have invested another $40 million in a four-year follow-up, and I believe over 80% of the original participants have joined. 'Brain health is a long game,' she added. 'It's hard to track, but over time, change can be meaningful.' By Sandee LaMotte, CNN
Globe and Mail
an hour ago
- Globe and Mail
Should You Buy American Express While It's Below $315?
Key Points American Express continues to report solid revenue growth, with younger consumers propelling the business forward. A strong brand and a powerful network effect support American Express' competitive position. The stock doesn't look cheap at the current price. 10 stocks we like better than American Express › American Express (NYSE: AXP) has been around for 175 years, which showcases the durability of its business model. It's not going to turn heads by posting outsized growth like a younger, more tech-driven company will. The credit card and financial services enterprise does have staying power, though. This stock has put up a phenomenal gain in the past five years, producing a total return of 244%. While I don't believe this kind of performance will repeat through the rest of this decade, there's no question that American Express is a high-quality business that deserves a closer look. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Should you buy the shares as they trade below $315 (as of July 25)? Warren Buffett's stamp of approval The great Warren Buffett has a stringent filter for what Berkshire Hathaway owns in its portfolio. So investors should take notice of the fact that American Express is one of the top holdings for the conglomerate. This means that the company must have some merits. One area worth mentioning is the company's durable performance in these uncertain economic times. Through the first six months of 2025, Amex's revenue increased 8.4% year over year to $34.8 billion. As mentioned, that growth isn't forcing investors to pick their jaws up off the floor. However, I do believe the gains are sustainable. American Express benefits from the general expansion in the overall economy, and from rising spending levels. The company can also "steal" market share from cash- and paper-based transactions -- the rise of digital payments helps Amex. It wouldn't be surprising to see this level of growth continue indefinitely. Recently, Amex has been resonating with younger consumers. Attracting a younger demographic can lead to a lucrative long-term relationship, especially as these customers' financial lives evolve over time, their wealth grows, and they gain more spending power. Leaning on key competitive advantages American Express has built a reputation for being a premium brand in the credit card space. There's a certain level of exclusivity and prestige that comes with being a cardholder. That's supported by high annual fees for its top cards, like the Platinum and the Gold. This naturally brings in more affluent customers who have lower credit risk and the ability to spend more money. The company also charges higher processing fees to merchants than competitors do. Even so, there are 100 million merchant locations that accept Amex payments, as they realize the benefit of having access to such a compelling customer base. In other words, you don't want to lose an Amex cardholder's business. American Express has a unique setup because it also runs the underlying payment infrastructure, connecting merchants with customers. Consequently, there's a network effect in play here. It's a positive feedback look, with more merchants creating more value for cardholders and vice versa. This makes it extremely difficult for American Express to be disrupted or become obsolete. Is the stock cheap or expensive? The past five years have been spectacular for Amex shareholders. But after such a huge gain, investors must assess the current situation with fresh eyes. Is the stock cheap or expensive with the price below $315? The price-to-earnings (P/E) ratio is a useful tool to analyze valuation. Right now, Amex's is 21.9, near its highest level in three years. I don't think the valuation presents a bargain opportunity. In fact, shares might be expensive. Amex's management team forecasts mid-teens earnings-per-share growth over the long term. Assuming it's a 15% annualized gain, which seems realistic, the stock will double in five years. That's with the P/E multiple staying constant. But there's a good chance it will contract, a trend that would lower the stock's return. Investors who are still bullish might want to consider a dollar-cost averaging approach. With this strategy, buying shares below $315 would have less of an effect in the long run. Should you invest $1,000 in American Express right now? Before you buy stock in American Express, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and American Express wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 28, 2025
CBC
an hour ago
- CBC
Why Trump's deals with the EU, Japan may not be templates for Canada in trade talks
Social Sharing U.S. President Donald Trump's successive announcements of deals setting baseline tariffs on the European Union and Japan are prompting questions about whether they're a road map for Canada to follow in trade talks. Trump and European Commission President Ursula von der Leyen described the bones of an agreement on Sunday. It sets across-the-board tariffs of 15 per cent on most European Union exports to the United States, along with a commitment by Europe to invest $600 billion US in the American economy and spend $750 billion on U.S. energy products — although there's plenty of fine print still to come. That makes it broadly comparable to the deal Trump announced last week with Japan: a 15 per cent across-the-board tariff and a Japanese commitment to invest $550 billion in the U.S. Trump was threatening to hit Europe with 30 per cent baseline tariffs and Japan with 25 per cent on Aug. 1, so both trading blocs are selling the deals as wins. Because Canada is facing the threat of 35 per cent tariffs on some goods on the same date, does that mean Canada should be aiming for a similar agreement? Prime Minister Mark Carney certainly isn't saying so. Asked whether any forthcoming deal will be "in the ballpark" of those 15 per cent baseline tariffs, he emphasized the differences between Europe's and Canada's trading relationship with the U.S. "We are in a different position, and that is why these negotiations ... are different," Carney said on Monday, citing Canada's geographical closeness and energy exports to the U.S. "Europe, in that agreement yesterday, made commitments to buy American energy," he said at a news conference in Prince Edward Island. "America needs Canadian energy." WATCH | Canada's trade talks with the U.S. are different from Europe's, Carney says: Carney says Canada is 'in a different position' than EU on trade deal with U.S. 15 hours ago Across-the-board tariffs 'difficult for Canada to accept' There are plenty of reasons why a 15 per cent baseline tariff rate is not something for Canada to aspire to, given that its economy is proportionally far more dependent on the U.S. market than Europe's and Japan's are. Jonathan O'Hara, an international trade lawyer in the Ottawa law office of McMillan LLP, said Canada should set its sights on a better deal than the EU or Japan negotiated since it's already so tightly integrated with the American economy. "On a broad level, having some kind of across-the-board tariffs, I think, would be very difficult for Canada to accept," O'Hara said in a weekend interview with CBC News. WATCH | Here's what's in Trump's tariff deal with the EU: Trump, EU reach trade deal framework 1 day ago Yet it appears that Canada doesn't actually face the prospect of tariffs that are truly across-the-board. That's because it has something that neither the European Union nor Japan have: an actual free-trade deal. Trump's "fentanyl emergency" tariffs, currently set at 25 per cent — which he's threatening to raise to 35 per cent on Friday — hit only those goods that don't comply with the rules of origin in the Canada-U.S.-Mexico Agreement (CUSMA). That means the vast bulk of Canada's exports to the U.S. are currently crossing the border tariff-free. Steel and aluminum tariffs a big question That may be why Carney's Liberal government does not feel the same sort of pressure as Europe and Japan to get a deal on Trump's timeline, said Drew Fagan, a professor at the University of Toronto's Munk School of Global Affairs and Public Policy. "Overall, the average tariff on Canadian goods going into the United States is about as low as any place in the world," he told CBC News. "What's important for us is that the [CUSMA] free-trade agreement continues to hold. Whether it will in the future, of course, is a fundamental question." The biggest exceptions to Canada's mostly tariff-free access to the U.S. are steel and aluminum, hit by Trump's 50 per cent global rate as he tries to prop up that sector at home. In their deals reached with the U.S., neither the EU nor Japan are let off the hook from that tariff. While Canada is surely angling for something better on steel and aluminum — such as the U.K.'s 25 per cent tariff, potentially headed to zero — the European and Japanese agreements suggest that will be tough to achieve. Carlo Dade, director of international policy at the University of Calgary's School of Public Policy, said Canada will likely face a tariff rate comparable to Europe's. "The Americans have decided to readjust the terms of trade," Dade said. "The price of access to the U.S. market is going up globally. It appears everyone is going to have to pay an increased cost." There are plenty of signs to suggest that the prospects are slim for Canada to reach a deal by Trump's deadline of Friday: Carney said the talks are complex, his top trade negotiators are downplaying the importance of the deadline and Trump himself is saying there may not be a deal at all.
